Stereotaxis (Stereotaxis) Cash-to-Debt

: 3.61 (As of Dec. 2023)

View and export this data going back to 2004. Start your Free Trial

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Stereotaxis's cash to debt ratio for the quarter that ended in Dec. 2023 was 3.61.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Stereotaxis could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Stereotaxis's Cash-to-Debt or its related term are showing as below:

STXS' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.31 Med: 6.65 Max: No Debt
Current: 3.61

During the past 13 years, Stereotaxis's highest Cash to Debt Ratio was No Debt. The lowest was 0.31. And the median was 6.65.

STXS's Cash-to-Debt is ranked better than
58.75% of 863 companies
in the Medical Devices & Instruments industry
Industry Median: 2.08 vs STXS: 3.61

Stereotaxis Cash-to-Debt Historical Data

The historical data trend for Stereotaxis's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Stereotaxis Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

6.96

9.88

6.34

4.85

3.61

Stereotaxis Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt																4.85	4.45	4.03	3.96	3.61

Competitive Comparison

For the Medical Instruments & Supplies subindustry, Stereotaxis's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Stereotaxis Cash-to-Debt Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Stereotaxis's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Stereotaxis's Cash-to-Debt falls into.

Stereotaxis Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Stereotaxis's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	19.818	/	(0.428	+	5.062)
	=	3.61

Stereotaxis's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	19.818	/	(0.428	+	5.062)
	=	3.61

Stereotaxis (AMEX:STXS) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Stereotaxis Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Stereotaxis's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Stereotaxis (Stereotaxis) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Stereotaxis Inc (AMEX:STXS) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

RJR1:Germany

Address

710 North Tucker Boulevard, Suite 110, St. Louis, MO, USA, 63101

Website

https://www.stereotaxis.com

Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. The company's mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The company's revenue generation is derived from the streams of Systems; Disposables, Royalty; and Sublease, of which a majority of revenue is generated from the Disposables, service and accessories stream. The company generates the majority of revenue from the United States.

Executives

Paul J Isaac	10 percent owner	530 FIFTH AVENUE, 20TH FLOOR, NEW YORK NY 10036
Myriam Curet	director	1020 KIFER ROAD, SUNNYVALE CA 94086
David Benfer	director	5 SELDEN AVENUE, BRANFORD CT 06404
Kimberly R. Peery	officer: Chief Financial Officer	C/O STEREOTAXIS, INC., 4320 FOREST PARK AVENUE: SUITE 100, ST. LOUIS MO 63108
Kevin M. Barry	officer: Chief Legal Officer & Secretar	4320 FOREST PARK AVENUE, 100, ST. LOUIS MO 63108
Ross B Levin	director	530 FIFTH AVENUE, 20TH FLOOR, NEW YORK NY 10036
Fariba Fischel Ghodsian	10 percent owner	10990 WILSHIRE BOULEVARD, SUITE 1400, LOS ANGELES CA 90024
Dafna Capital Management Llc	10 percent owner	10990 WILSHIRE BOULEVARD, SUITE 1400, LOS ANGELES CA 90024
David Leo Fischel	director	10990 WILSHIRE BOULEVARD, SUITE 1400, LOS ANGELES CA 90024
Arun Swarup Menawat	director	2412 EIGHTH LINE, OAKVILLE A6 L6H6S9
Joe E Kiani	director	4320 FOREST PARK AVENUE, SUITE 100, ST. LOUIS MO 63108
Paul Brathwaite	officer: VP Research & Development	C/O STEREOTAXIS, INC., 4320 FOREST PARK AVENUE, SUITE 100, ST. LOUIS MO 63108
Martin C Stammer	officer: Chief Financial Officer	C/O STEREOTAXIS, INC., 4320 FOREST PARK AVENUE, SUITE 100, ST. LOUIS MO 63108
Nathan Fischel	director	10990 WILSHIRE BOULEVARD, SUITE 1400, LOS ANGELES CA 90024
Duane Desisto	director	C/O INSULET CORPORATION, 9 OAK PARK DRIVE, BEDFORD MA 01730